Skip to main content
Top
Published in: European Surgery 3/2018

01-06-2018 | main topic

Patient selection and perioperative optimisation in surgery for colorectal liver metastases

Authors: Dr. Benjamin D Jones, BMBS, Robert Jones, PhD FRCS, Declan FJ Dunne, FRCS, Tim Astles, MBChB MRCP FRCA FFICM, Stephen W Fenwick, FRCS, Graeme J Poston, MS, Hassan Z Malik, FRCS

Published in: European Surgery | Issue 3/2018

Login to get access

Summary

Background

Clinical decision-making around the management of liver-limited stage IV colorectal cancer involves careful assessment of the potential risks and benefits of surgery. This balance can often be optimised through appropriate patient selection to ensure long-term benefit of any operation, with fastidious perioperative care to minimize risk.

Methods

We reviewed selected relevant articles from the existing literature.

Results

Multi-platform imaging is routinely used to determine distribution of disease and whether lesions are technically resectable, but what remains less clear is how to identify patients in whom resection is likely to deliver long-term benefits. A number of prognostic markers have been identified, with growing interest in direct assessment of tumour biology; genotyping of RAS status is routine in specific situations. Following a multidisciplinary team decision to proceed to surgery, patients undergo perioperative assessment and optimisation. Cardiopulmonary exercise testing helps to stratify perioperative risk: patients with low uptake of oxygen at the anaerobic threshold are known to have worse perioperative outcomes, and prehabilitation may offer the chance to reduce this risk. Intraoperative anaesthetic management is on a patient-by-patient basis but sub-normal hydration, epidural anaesthesia and steroids play a key role. Enhanced recovery after surgery programmes have improved perioperative outcomes while providing a potential economic benefit.

Conclusion

Despite very good perioperative results, surgical management is not curative for the majority of patients, highlighting the need to further refine patient selection and definition of treatment aim on a patient-by-patient basis.
Literature
1.
go back to reference Haraldsdottir S, Einarsdottir HM, Smaradottir A, Gunnlaugsson A, Halfdanarson TR. Colorectal cancer—review. Laeknabladid. 2014;100(2):75–82.PubMed Haraldsdottir S, Einarsdottir HM, Smaradottir A, Gunnlaugsson A, Halfdanarson TR. Colorectal cancer—review. Laeknabladid. 2014;100(2):75–82.PubMed
2.
3.
go back to reference Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.CrossRefPubMedPubMedCentral Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.CrossRefPubMedPubMedCentral
4.
go back to reference Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–74.CrossRefPubMed Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–74.CrossRefPubMed
5.
6.
go back to reference Jones RP, Jackson R, Dunne DFJ, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg. 2012;99:477–86.CrossRefPubMed Jones RP, Jackson R, Dunne DFJ, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg. 2012;99:477–86.CrossRefPubMed
7.
go back to reference Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus ce-tuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.CrossRefPubMed Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus ce-tuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.CrossRefPubMed
8.
go back to reference Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.PubMedPubMedCentral Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.PubMedPubMedCentral
9.
go back to reference Dunne DF, Yip VS, Jones RP, et al. Enhanced recovery in the resection of colorectal liver metastases. J Surg Oncol. 2014;110(2):197–202.CrossRefPubMed Dunne DF, Yip VS, Jones RP, et al. Enhanced recovery in the resection of colorectal liver metastases. J Surg Oncol. 2014;110(2):197–202.CrossRefPubMed
10.
go back to reference Jones RP, Brudvik KW, Franklin JM, Poston GJ. Precision surgery for colorectal liver metastases: opportunities and challenges of omics-based decision making. Eur J Surg Oncol. 2017;43(5):875–83.CrossRefPubMed Jones RP, Brudvik KW, Franklin JM, Poston GJ. Precision surgery for colorectal liver metastases: opportunities and challenges of omics-based decision making. Eur J Surg Oncol. 2017;43(5):875–83.CrossRefPubMed
11.
go back to reference Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18.CrossRefPubMedPubMedCentral Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18.CrossRefPubMedPubMedCentral
12.
13.
go back to reference Roberts KJ, White A, Cockbain A, et al. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg. 2014;101(7):856–66.CrossRefPubMed Roberts KJ, White A, Cockbain A, et al. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg. 2014;101(7):856–66.CrossRefPubMed
14.
go back to reference Schreckenbach T, Malkomes P, Bechstein WO, Woeste G, Schnitzbauer AA, Ulrich F. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg Today. 2015;45(12):1527–34.CrossRefPubMed Schreckenbach T, Malkomes P, Bechstein WO, Woeste G, Schnitzbauer AA, Ulrich F. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg Today. 2015;45(12):1527–34.CrossRefPubMed
15.
go back to reference Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.CrossRefPubMed Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.CrossRefPubMed
16.
go back to reference Andreou A, Kopetz S, Maru DM, et al. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012;256(4):642–50.CrossRefPubMed Andreou A, Kopetz S, Maru DM, et al. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012;256(4):642–50.CrossRefPubMed
18.
go back to reference Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–26. discussion 626–7.CrossRefPubMed Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–26. discussion 626–7.CrossRefPubMed
19.
go back to reference Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017; https://doi.org/10.1200/jco.2016.71.9807.PubMedCrossRef Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017; https://​doi.​org/​10.​1200/​jco.​2016.​71.​9807.PubMedCrossRef
20.
go back to reference National Comprehensive Cancer Network. NCCN guidelines: colon cancer, version 2.2015. 2015. National Comprehensive Cancer Network. NCCN guidelines: colon cancer, version 2.2015. 2015.
21.
go back to reference Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–26.CrossRefPubMed Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–26.CrossRefPubMed
22.
go back to reference Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175–83.CrossRefPubMed Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175–83.CrossRefPubMed
25.
go back to reference Pugh SA, Shinkins B, Fuller A, Mellor J, Mant D, Primrose JN. Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial. Ann Surg. 2016;263(6):1143–7.CrossRefPubMed Pugh SA, Shinkins B, Fuller A, Mellor J, Mant D, Primrose JN. Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial. Ann Surg. 2016;263(6):1143–7.CrossRefPubMed
26.
go back to reference Poston GJ, Tait D, O’Connell S, Bennett A, Berendse S, Guideline Development Group. Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ. 2011;343:d6751.CrossRefPubMed Poston GJ, Tait D, O’Connell S, Bennett A, Berendse S, Guideline Development Group. Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ. 2011;343:d6751.CrossRefPubMed
27.
go back to reference Jones RP, Vauthey JN, Adam R, et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg. 2012;99(9):1263–9.CrossRefPubMed Jones RP, Vauthey JN, Adam R, et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg. 2012;99(9):1263–9.CrossRefPubMed
28.
go back to reference Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47.CrossRefPubMed Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47.CrossRefPubMed
29.
go back to reference Choti MA, Thomas M, Wong SL, et al. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann Surg Oncol. 2015;23(2):375–81.CrossRefPubMed Choti MA, Thomas M, Wong SL, et al. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann Surg Oncol. 2015;23(2):375–81.CrossRefPubMed
30.
go back to reference Dunne DF, Jones RP, Lythgoe DT, et al. Cardiopulmonary exercise testing before liver surgery. J Surg Oncol. 2014;110(4):439–44.CrossRefPubMed Dunne DF, Jones RP, Lythgoe DT, et al. Cardiopulmonary exercise testing before liver surgery. J Surg Oncol. 2014;110(4):439–44.CrossRefPubMed
31.
go back to reference Snowden CP, Prentis J, Jacques B, et al. Cardiorespiratory fitness predicts mortality and hospital length of stay after major elective surgery in older people. Ann Surg. 2013;257(6):999–1004.CrossRefPubMed Snowden CP, Prentis J, Jacques B, et al. Cardiorespiratory fitness predicts mortality and hospital length of stay after major elective surgery in older people. Ann Surg. 2013;257(6):999–1004.CrossRefPubMed
32.
go back to reference Kasivisvanathan R, Abbassi-Ghadi N, McLeod AD, et al. Cardiopulmonary exercise testing for predicting postoperative morbidity in patients undergoing hepatic resection surgery. HPB (Oxford). 2015;17(7):637–43.CrossRef Kasivisvanathan R, Abbassi-Ghadi N, McLeod AD, et al. Cardiopulmonary exercise testing for predicting postoperative morbidity in patients undergoing hepatic resection surgery. HPB (Oxford). 2015;17(7):637–43.CrossRef
33.
go back to reference Junejo MA, Mason JM, Sheen AJ, et al. Cardiopulmonary exercise testing for preoperative risk assessment before hepatic resection. Br J Surg. 2012;99(8):1097–104.CrossRefPubMed Junejo MA, Mason JM, Sheen AJ, et al. Cardiopulmonary exercise testing for preoperative risk assessment before hepatic resection. Br J Surg. 2012;99(8):1097–104.CrossRefPubMed
34.
go back to reference Dunne DF, Jack S, Jones RP, et al. Randomized clinical trial of prehabilitation before planned liver resection. Br J Surg. 2016;103(5):504–12.CrossRefPubMed Dunne DF, Jack S, Jones RP, et al. Randomized clinical trial of prehabilitation before planned liver resection. Br J Surg. 2016;103(5):504–12.CrossRefPubMed
35.
go back to reference Chen H, Merchant NB, Didolkar MS. Hepatic resection using intermittent vascular inflow occlusion and low central venous pressure anesthesia improves morbidity and mortality. J Gastrointest Surg. 2000;4(2):162–7.CrossRefPubMed Chen H, Merchant NB, Didolkar MS. Hepatic resection using intermittent vascular inflow occlusion and low central venous pressure anesthesia improves morbidity and mortality. J Gastrointest Surg. 2000;4(2):162–7.CrossRefPubMed
36.
go back to reference Melendez JA, Arslan V, Fischer ME, et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg. 1998;187:620–5.CrossRefPubMed Melendez JA, Arslan V, Fischer ME, et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg. 1998;187:620–5.CrossRefPubMed
37.
go back to reference Feltracco P, Brezzi ML, Barbieri S, Serra E, Milevoj M, Ori C. Epidural anesthesia and analgesia in liver resection and living donor hepatectomy. Transplant Proc. 2008;40(4):1165–8.CrossRefPubMed Feltracco P, Brezzi ML, Barbieri S, Serra E, Milevoj M, Ori C. Epidural anesthesia and analgesia in liver resection and living donor hepatectomy. Transplant Proc. 2008;40(4):1165–8.CrossRefPubMed
38.
go back to reference Li H, Wei Y, Li B. Preoperative steroid administration in liver resection: a systematic review and meta-analysis. Hepatogastroenterology. 2013;60(121):160–9.PubMed Li H, Wei Y, Li B. Preoperative steroid administration in liver resection: a systematic review and meta-analysis. Hepatogastroenterology. 2013;60(121):160–9.PubMed
39.
go back to reference Adamina M, Kehlet H, Tomlinson GA, Senagore AJ, Delaney CP. Enhanced recovery pathways optimize health outcomes and resource utilization: a meta-analysis of randomized controlled trials in colorectal surgery. Surgery. 2011;149(6):830–40.CrossRefPubMed Adamina M, Kehlet H, Tomlinson GA, Senagore AJ, Delaney CP. Enhanced recovery pathways optimize health outcomes and resource utilization: a meta-analysis of randomized controlled trials in colorectal surgery. Surgery. 2011;149(6):830–40.CrossRefPubMed
40.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral
41.
go back to reference Ishii M, Mizuguchi T, Harada K, Ota S, Meguro M, Ueki T. Comprehensive review of post-liver resection surgical complications and a new universal classification and grading system. World J Hepatol. 2014;6(10):745–51.CrossRefPubMedPubMedCentral Ishii M, Mizuguchi T, Harada K, Ota S, Meguro M, Ueki T. Comprehensive review of post-liver resection surgical complications and a new universal classification and grading system. World J Hepatol. 2014;6(10):745–51.CrossRefPubMedPubMedCentral
42.
go back to reference Kobayashi S, Gotohda N, Nakagohri T, Takahashi S, Konishi M, Kinoshita T. Risk factors of surgical site infection after hepatectomy for liver cancers. World J Surg. 2009;33(2):312–7.CrossRefPubMed Kobayashi S, Gotohda N, Nakagohri T, Takahashi S, Konishi M, Kinoshita T. Risk factors of surgical site infection after hepatectomy for liver cancers. World J Surg. 2009;33(2):312–7.CrossRefPubMed
43.
go back to reference Karavokyros I, Orfanos S, Angelou A, et al. Incidence and risk factors for organ/space infection after radiofrequency-assisted hepatectomy or ablation of liver tumors in a single center: more than meets the eye. Front Surg. 2017;4:17.CrossRefPubMedPubMedCentral Karavokyros I, Orfanos S, Angelou A, et al. Incidence and risk factors for organ/space infection after radiofrequency-assisted hepatectomy or ablation of liver tumors in a single center: more than meets the eye. Front Surg. 2017;4:17.CrossRefPubMedPubMedCentral
44.
go back to reference Nanashima A, Arai J, Oyama S, et al. Associated factors with surgical site infections after hepatectomy: predictions and countermeasures by a retrospective cohort study. Int J Surg. 2014;12(4):310–4.CrossRefPubMed Nanashima A, Arai J, Oyama S, et al. Associated factors with surgical site infections after hepatectomy: predictions and countermeasures by a retrospective cohort study. Int J Surg. 2014;12(4):310–4.CrossRefPubMed
45.
go back to reference Hoekstra LT, Wakkie T, Busch OR, Gouma DJ, Beuers U, van Gulik T. Predictors of posthepatectomy ascites with or without previous portal vein embolization. Dig Surg. 2012;29(6):468–74.CrossRefPubMed Hoekstra LT, Wakkie T, Busch OR, Gouma DJ, Beuers U, van Gulik T. Predictors of posthepatectomy ascites with or without previous portal vein embolization. Dig Surg. 2012;29(6):468–74.CrossRefPubMed
47.
go back to reference Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? Dig Surg. 2012;29(1):6–17.CrossRefPubMed Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? Dig Surg. 2012;29(1):6–17.CrossRefPubMed
Metadata
Title
Patient selection and perioperative optimisation in surgery for colorectal liver metastases
Authors
Dr. Benjamin D Jones, BMBS
Robert Jones, PhD FRCS
Declan FJ Dunne, FRCS
Tim Astles, MBChB MRCP FRCA FFICM
Stephen W Fenwick, FRCS
Graeme J Poston, MS
Hassan Z Malik, FRCS
Publication date
01-06-2018
Publisher
Springer Vienna
Published in
European Surgery / Issue 3/2018
Print ISSN: 1682-8631
Electronic ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-018-0539-8

Other articles of this Issue 3/2018

European Surgery 3/2018 Go to the issue